Last reviewed · How we verify
Fluticason
At a glance
| Generic name | Fluticason |
|---|---|
| Sponsor | Creighton University |
| Target | Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Allergic asthma
- Allergic rhinitis
- Asthma management
- Atopic dermatitis
- Bronchospasm Prevention with COPD
- COPD Associated with Chronic Bronchitis
- Chronic Non-Allergic Rhinitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Non-allergic asthma
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Pulmonary emphysema
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- Ear, nose, and throat adverse events
- Tremor
- Nervousness
- Headache
- Palpitations
- Neurology adverse events
- Muscle injuries
- Musculoskeletal adverse events
- Gastrointestinal adverse events
- Lower respiratory adverse events
- Throat irritation
- Ear, nose, and throat infections
Serious adverse events
- Pneumonia
- Fractures
- Compressed nerve syndromes
- Keratitis and conjunctivitis
- Oral ulcerations
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (PHASE3)
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticason CI brief — competitive landscape report
- Fluticason updates RSS · CI watch RSS
- Creighton University portfolio CI